Chong Kun Dang Pharma - Public Comps and Valuation Multiples

Chong Kun Dang Pharma Overview

About Chong Kun Dang Pharma

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Founded

1941

HQ

Employees

n/a

Website

chongkundang.en.ec21.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.2B

LTM EBITDA $79.2M

EV

$810M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Chong Kun Dang Pharma Financials

As of December 2025, Chong Kun Dang Pharma reported last 12-month revenue of $1.2B and EBITDA of $79.2M.

In the same period, Chong Kun Dang Pharma generated $367M in LTM gross profit and $47.7M in net income.

See Chong Kun Dang Pharma valuation multiples based on analyst estimates

Chong Kun Dang Pharma P&L

In the most recent fiscal year, Chong Kun Dang Pharma reported revenue of $1.1B and EBITDA of $104M.

Chong Kun Dang Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Chong Kun Dang Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$1.2B	XXX	$1.1B	XXX	XXX	XXX
Gross Profit	$367M	XXX	$368M	XXX	XXX	XXX
Gross Margin	32%	XXX	34%	XXX	XXX	XXX
EBITDA	$79.2M	XXX	$104M	XXX	XXX	XXX
EBITDA Margin	7%	XXX	9%	XXX	XXX	XXX
EBIT	$51.5M	XXX	$68.7M	XXX	XXX	XXX
EBIT Margin	4%	XXX	6%	XXX	XXX	XXX
Net Profit	$47.7M	XXX	$75.3M	XXX	XXX	XXX
Net Margin	4%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Chong Kun Dang Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.2B. EBITDA for the last twelve months was $79.2M. In the most recent fiscal year, Chong Kun Dang Pharma achieved $1.1B in revenue and $104M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$1.2B	Analyst estimates available to subscribers	$1.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$367M	Analyst estimates available to subscribers	$368M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	31.5% gross margin	Analyst estimates available to subscribers	33.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$79.2M	Analyst estimates available to subscribers	$104M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	6.8% EBITDA margin	Analyst estimates available to subscribers	9.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$51.5M	Analyst estimates available to subscribers	$68.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	4.4% EBIT margin	Analyst estimates available to subscribers	6.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$47.7M	Analyst estimates available to subscribers	$75.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	4.1% net profit margin	Analyst estimates available to subscribers	6.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Chong Kun Dang Pharma

This financial data table provides comprehensive performance metrics for Chong Kun Dang Pharma, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Chong Kun Dang Pharma generated $1.2B in revenue over the last twelve months.
The company achieved $79.2M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $367M.
Net income over the last twelve months reached $47.7M.

Fiscal Year Performance

In the most recent fiscal year, Chong Kun Dang Pharma reported $1.1B in total revenue.
Fiscal year EBITDA was $104M.
The company maintained a gross profit margin of 33.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 9.5%.
Net profit margin reached 6.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Chong Kun Dang Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Chong Kun Dang Pharma Stock Performance

Chong Kun Dang Pharma has current market cap of KRW 1.10T (or $758M), and EV of KRW 1.17T (or $810M).

Market Cap Evolution

Chong Kun Dang Pharma Stock Data

As of January 16, 2026, Chong Kun Dang Pharma's stock price is KRW 83300 (or $58).

See Chong Kun Dang Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$810M	$758M	XXX	XXX	XXX	XXX	$3.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Chong Kun Dang Pharma Valuation Multiples

Chong Kun Dang Pharma's trades at 0.7x EV/Revenue multiple, and 10.2x EV/EBITDA.

See valuation multiples for Chong Kun Dang Pharma and 15K+ public comps

Chong Kun Dang Pharma Financial Valuation Multiples

As of January 16, 2026, Chong Kun Dang Pharma has market cap of $758M and EV of $810M.

Equity research analysts estimate Chong Kun Dang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Chong Kun Dang Pharma has a P/E ratio of 15.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$758M	XXX	$758M	XXX	XXX	XXX
EV (current)	$810M	XXX	$810M	XXX	XXX	XXX
EV/Revenue	0.7x	XXX	0.7x	XXX	XXX	XXX
EV/EBITDA	10.2x	XXX	10.2x	XXX	XXX	XXX
EV/EBIT	15.7x	XXX	15.7x	XXX	XXX	XXX
EV/Gross Profit	2.2x	XXX	n/a	XXX	XXX	XXX
P/E	15.9x	XXX	15.9x	XXX	XXX	XXX
EV/FCF	29.2x	XXX	29.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chong Kun Dang Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Chong Kun Dang Pharma Margins & Growth Rates

Chong Kun Dang Pharma's last 12 month revenue growth is 4%

Chong Kun Dang Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Chong Kun Dang Pharma's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chong Kun Dang Pharma's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Chong Kun Dang Pharma and other 15K+ public comps

Chong Kun Dang Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	4%	XXX	5%	XXX	XXX	XXX
EBITDA Margin	7%	XXX	7%	XXX	XXX	XXX
EBITDA Growth	9%	XXX	-37%	XXX	XXX	XXX
Rule of 40	21%	XXX	11%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	17%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	27%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial